Bruker is a performace leader in preclinical imaging instrumentation. Bruker offers nine imaging modalities: PET, SPECT, CT, MRI, MPI, fluorescence, luminiscence, radioisotipic imaging and X-ray.
Accelerate to discover
Back to filter
Show all topics (10)
Related topics
InAlyzer to evaluate G6PD activity in relation with frailty
Mar 28, 2023
InAlyzer is body densitometry instrument for lab animals, equipped with 2 X-Ray sources and able to provide valuable...
Cardiomyocyte isolation using Cellenion’s cellenONE instrument
Mar 24, 2023
The cellenONE platform is ideal for the isolation of fragile and heterogeneous cell size populations, such as...
ACCELA educational webinar: Unlocking Spatial Biology with RareCyte Orion
Mar 16, 2023
Experience Spatial Biology with Orion Multiplex Imaging. Orion is a benchtop, high...
Recorded webinar: Anesthesia Considerations in Small Animal Imaging
Mar 13, 2023
Anesthesia settings and operation of Optical Imaging Systems: methods, animal handling, safety and regulatory...
Introducing Cytek Human Leukocyte Kit, the first ever 15-color lyse no-wash assay
Mar 13, 2023
This kit has been designed to enumerate all major leukocyte subsets and it mirrors and expands on those identified in a...
Immunofluorescence Imaging for Rare Cell Detection with CyteFinder II
Mar 7, 2023
CyteFinder II Instruments are high speed, whole slide imaging systems with options for liquid biopsy analysis and...
NanoCellect Webinar: Optimizing the Cell Line Development Process with Microfluidic Cell Sorting
Mar 3, 2023
Single-cell selection and cloning are required for bioengineering workflows such as antibody production, cell therapy,...
New Kit for Bacterial analysis expands capability of Guava Muse flow cytometer
Feb 20, 2023
With the Guava Muse cell analyzer, you can now achieve highly quantitative results at a fraction of the price, effort,...
Preclinical PET imaging in studies of candidate therapeutics
Jun 22, 2017
Clinical and preclinical non-invasive PET imaging is employed in the development and validation of therapeutic agents for cancer and neurological disorders, and a range of other diseases. Reported studies have used numerous agents including FDG, FLT, FMISO and FAZA as early biomarkers of drug efficacy. Preclinical PET imaging has been proven in studies of therapeutic targeting and biodistribution, drug target interactions, pharmacodynamics and toxicology. These methods have helped facilitate the development of therapeutic agents that are now clinically available. Probably two of the most common uses of preclinical PET imaging in drug discovery are studies of compound targeting and biodistribution and therapeutic efficacy. In the article, you can find a brief introduction to preclinical PET imaging for such studies.
Related technologies: PET, SPECT, CT
Get more info
Brand profile
